Pharmaceuticals, Biotechnology and Life Sciences
A Munich-based biosimilar developer just signed a strategic manufacturing partnership with an Indian CDMO. According to industry analysts, it is...
A Munich-based biosimilar developer just signed a strategic manufacturing partnership with an Indian CDMO. According to industry analysts, it is not the first such deal, and it will not be...
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according...
In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to...
A Munich-based biosimilar developer just signed a strategic manufacturing partnership with an Indian CDMO. According to industry analysts, it is not the first such deal, and it will not be the last. The question is what Europe gets — and what it gives up — as the shift accelerates?
The 21-mile-wide waterway that supplies Europe’s medicine cabinet is not reopening — it is effectively closed once more, live maritime tracking data and intelligence reports show. The crisis that began in February has evolved into an active theatre of war with no clear end in sight.
Poolbeg Pharma (AIM: POLB) said on 13 July that the first patient has been dosed in its POLB 001 TOPICAL trial, according to the company’s RNS statement, and that University College London Hospital has now also been activated as a clinical trial site, with additional sites expected to open imminently. Investor reaction will hinge less on the milestone itself — dosing a first patient is table stakes for any trial — and more on what happens over the next six to eight weeks, since interim data is still on track for late summer.
A new white paper from one of the world’s most influential credit agencies maps the forces tearing apart pharmaceutical supply chains. The diagnosis is accurate.
By Pharmaceutical Daily Editorial Staff As the conflict in the Middle East enters its second month, the pharmaceutical industry across…
BioPharma Credit deploys another $125 million into a pre-approval biotech. But the company it just backed is the one whose stock fell more than 50% on its Phase 3 data.
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
The Finnish biotech is going back to shareholders with a fully covered offering, aiming to fund a pivotal Phase II trial in high-risk myelodysplastic syndrome — and postponing its AGM for reasons that are anything but routine
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
